TANO-TAC · Thrombolytic Nanobody Therapy for Dissolving All Types of Blood Clots

TargED Biopharmaceuticals B.V., a spin-off from UMC Utrecht, is developing TGD001, an innovative first-in-class drug designed to treat all types of blood clots associated with thrombosis, a leading global cause of death that currently has limited effective treatments. TGD001 has shown superior results in preclinical studies, demonstrating high precision, safety, and efficacy, and TargED has raised over €45 million to fund its clinical trials, moving toward market readiness.Unlike existing therapies, TGD001 has the ability to target both von Willebrand Factor (vWF) and fibrin, addressing the varied composition of blood clots. This dual-target mechanism enables TGD001 to effectively dissolve both macrovascular and microvascular clots, making it a ""one-drug-fits-all"" solution for thrombotic conditions. This comprehensive approach extends the treatment window, reduces bleeding risks, and makes it suitable for a wider range of patients compared to existing therapies.TGD001 has received Orphan Drug Designation from the European Medicines Agency for thrombotic thrombocytopenic purpura (TTP), granting 10 years of market exclusivity, regulatory support, and financial incentives, significantly accelerating its development for immune Thrombotic Thrombocytopenic Purpura (iTTP), a rare and severe form of TTP.Led by an experienced team, TargED is advancing TGD001 through clinical development, targeting iTTP and Acute Ischemic Stroke (AIS), indications on opposite ends of the clot composition spectrum, with global potential peak revenues of €421 million and €5.2 billion respectively. TargED’s core strategy is to advance TGD001 through to MAA/BLA submission independently. To further support the development, TargED plans a €25M Series B funding round to execute Phase 2a trials and a 1000L GMP manufacturing run to scale production. EIC funding is crucial to bridge the funding valley of death, accelerate clinical development, and ensure timely market entry and patient access.""